Antibiotic development, stewardship advocates see window of opportunity

  22 April 2021

The pandemic isn’t over yet, but with more and more Americans getting vaccinated against COVID-19 and the light at the end of the pandemic tunnel becoming a little brighter every day—at least in the United States—many clinicians, scientists, and public health advocates are calling for renewed attention to an infectious disease threat that was in the spotlight before the pandemic arrived.

Prior to the pandemic, antimicrobial resistance (AMR) was considered one of the major looming health threats facing the world, if not the looming threat. But over the past year, COVID-19, and its multifaceted impact on society, has pushed AMR further back on the agenda, both for the public and policy makers.

At the same time, however, the pandemic is also providing AMR advocates and experts with a new opportunity to highlight the growing threat of drug-resistant bacteria.

Further reading: CIDRAP
Author(s): Chris Dall
Effective Surveillance   Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition

CDD VAULT Complexity Simplified





Technology Database

Display your AMR Technology, Product and Service

 

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

 

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!